KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Asset Writedowns and Impairment (2020 - 2025)

Historic Asset Writedowns and Impairment for Boston Scientific (BSX) over the last 6 years, with Q4 2025 value amounting to $51.0 million.

  • Boston Scientific's Asset Writedowns and Impairment fell 5363.64% to $51.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $188.0 million, marking a year-over-year increase of 6936.94%. This contributed to the annual value of $124.0 million for FY2025, which is 6787.56% down from last year.
  • According to the latest figures from Q4 2025, Boston Scientific's Asset Writedowns and Impairment is $51.0 million, which was down 5363.64% from $27.0 million recorded in Q3 2025.
  • Boston Scientific's 5-year Asset Writedowns and Impairment high stood at $197.0 million for Q4 2021, and its period low was $1.0 million during Q3 2023.
  • For the 5-year period, Boston Scientific's Asset Writedowns and Impairment averaged around $85.5 million, with its median value being $80.5 million (2024).
  • In the last 5 years, Boston Scientific's Asset Writedowns and Impairment soared by 14320.99% in 2021 and then tumbled by 9920.0% in 2023.
  • Quarter analysis of 5 years shows Boston Scientific's Asset Writedowns and Impairment stood at $197.0 million in 2021, then tumbled by 36.55% to $125.0 million in 2022, then tumbled by 99.2% to $1.0 million in 2023, then surged by 10900.0% to $110.0 million in 2024, then crashed by 53.64% to $51.0 million in 2025.
  • Its last three reported values are $51.0 million in Q4 2025, $27.0 million for Q3 2025, and $110.0 million during Q4 2024.